Please assess the completion status of the following clinical trial:

Trial Title: Acute Montelukast in Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute Asthma exacerbation requiring hospitalisation~Exclusion Criteria:~* Smoking history greater than or equal to 10 pack years~* Presenting PEFR greater than or equal to 75% predicted / best~* Failure to demonstrate greater than or equal to 15% variability in PEFR or FEV during the study~* Any significant and active pulmonary pathology other than asthma~* Pregnancy or breastfeeding~* Intended pregnancy or inability to take adequate precautions against conception~* Patient already on Montelukast~* Patient already on Phenobarbitone~* Patient already on Rifampicin~* Patient already on Phenytoin~* Chronic airflow limitation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Montelukast (Type: ACTIVE_COMPARATOR): 1 study capsule at study entry Montelukast 10mg and a further study capsule at 10pm for four weeks
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).